Drugs / Sm-TSP-2
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03110757 | May 2018 → Nov 2019 | intestinal schistosomiasis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02337855 | Feb 2015 → Jan 2017 | intestinal schistosomiasis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03910972 | Oct 2019 → Nov 2024 | Schistosoma mansoni infectious disease | Baylor College of Medicine | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sm-TSP-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03110757 ↗ |
| Known as | Sm-TSP-2/Alhydrogel | “Recombinant Schistosoma mansoni Tetraspanin-2 formulated on Alhydrogel (Sm-TSP-2/Alhydrogel) is being developed to prevent intestinal and hepatic disease caused by S. mansoni.” PMID 36996185 ↗ Mar 2023 |
| Modality | Vaccine | “Sm-TSP-2 vaccine” NCT02337855 ↗ |
| Route | Intramuscular | “single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel® on Day1, 57 and 113” NCT02337855 ↗ |